Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ACADEMIA
ACADEMIA
- Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
August 16, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Japan KOL Pins Hopes on Pemazyre as 1st Biliary Tract Cancer Drug in 9 Years
July 16, 2021
- Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
- 11% of Japanese COVID-19 Vaccine Hesitant, 74% Fret Adverse Reactions: Survey
July 6, 2021
- Pregnant Women Can Get COVID-19 Vaccinations: Japan OB/GYN Societies
June 29, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
- Japan Researchers Produce “Super Neutralizing Antibodies”
June 17, 2021
- As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
- Cancer Patients Have Lower Antibody Titers against Coronavirus: NCC
June 3, 2021
- NCC, 5 Other Institutions Forge Genome Cohort of 366,000 People
May 28, 2021
- Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
- New AMR Prevention Technology Could Contribute to Antiviral Development; Application to COVID-19 Meds Expected: Professor
May 17, 2021
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- 3 Existing Drugs Show Inhibitory Effects for SARS-CoV-2 in iPSC Screening
April 8, 2021
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…